Latest News-I-Mab Mediaroom_Page

I-Mab Announces Participation at Jefferies and Piper Conferences in November

ROCKVILLE, Md. and SHANGHAI, China, Nov. 6, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company...

2023-11-06 21:00 1797

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)

* FDA granted Breakthrough Therapy Designation for felzartamab in PMN upon positive clinical data...

2023-11-02 20:00 1510

I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023

ROCKVILLE, MD, U.S. and SHANGHAI, China, Nov. 1, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Co...

2023-11-01 20:00 2047

I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023

ROCKVILLE, Md. and SHANGHAI, China, Oct. 16, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Compan...

2023-10-16 20:00 2198

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503

- Among 14 efficacy-evaluable patients in the ongoing Phase 1 study, one achieved a complete...

2023-10-10 20:00 1803

I-Mab Announces Upcoming Participation at September Conferences

ROCKVILLE, Md. and SHANGHAI, Sept. 5, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), is...

2023-09-05 20:00 1726

I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates

* Significant progress made year-to-date on key clinical assets: ‐ Uliledlimab (CD73 antib...

2023-08-17 18:00 4688

I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023

ROCKVILLE, Md. and SHANGHAI, Aug. 8, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a c...

2023-08-08 20:00 1942

I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC

GAITHERSBURG, Md. and SHANGHAI, July 5, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), ...

2023-07-05 20:00 2216

I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC

I-Mab Announces the Appointment of Raj Kannan as CEO

GAITHERSBURG, Md. and SHANGHAI, June 22, 2023 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nas...

2023-06-22 20:00 2892

I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023

- Uliledlimab is a differentiated monoclonal antibody designed to target CD73 and promote stronger...

2023-05-26 05:01 2633

I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome

GAITHERSBURG, Md. and SHANGHAI, Sept, 13, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB)...

2022-09-13 20:00 2488

Latest News

I-Mab Announces Participation at Jefferies and Piper Conferences in November

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)

I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023

I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503

I-Mab Announces Upcoming Participation at September Conferences

I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates

I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023

I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC

I-Mab Announces the Appointment of Raj Kannan as CEO

I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023

I-MAB Filed 2022 Annual Report on Form 20-F

I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023

I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon

I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022

I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023

MSCI ESG Updated I-Mab to "A" Rating

I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022

I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome